Literature DB >> 17267744

Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients.

Chih-Ching Lin1, Chao-Fu Chang, Ming-Yu Lai, Tzen-Wen Chen, Pui-Ching Lee, Wu-Chang Yang.   

Abstract

Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in hemodialysis (HD) patients. Many methods of thermal therapy have been tried for improving Qa but with limited effects. This randomized trial was designed to evaluate the effect of far-infrared (FIR) therapy on access flow and patency of the native arteriovenous fistula (AVF). A total of 145 HD patients were enrolled with 73 in the control group and 72 in the FIR group. A WS TY101 FIR emitter was used for 40 min, and hemodynamic parameters were measured by the Transonic HD(02) monitor during HD. The Qa(1)/Qa(2) and Qa(3)/Qa(4) were defined as the Qa measured at the beginning/at 40 min later in the HD session before the initiation and at the end of the study, respectively. The incremental change of Qa in the single HD session with FIR therapy was significantly higher than that without FIR therapy (13.2 +/- 114.7 versus -33.4 +/- 132.3 ml/min; P = 0.021). In comparison with control subjects, patients who received FIR therapy for 1 yr had (1) a lower incidence (12.5 versus 30.1%; P < 0.01) and relative incidence (one episode per 67.7 versus one episode per 26.7 patient-months; P = 0.03) of AVF malfunction; (2) higher values of the following parameters, including Delta(Qa(4) - Qa(3)) (36.2 +/- 82.4 versus -12.7 +/- 153.6 ml/min; P = 0.027), Delta(Qa(3) - Qa(1)) (36.3 +/- 166.2 versus -51.7 +/- 283.1 ml/min; P = 0.035), Delta(Qa(4) - Qa(2)) (99.2 +/- 144.4 versus -47.5 +/- 244.5 ml/min; P < 0.001), and Delta(Qa(4) - Qa(2)) - Delta(Qa(3) - Qa(1)) (62.9 +/- 111.6 versus 4.1 +/- 184.5 ml/min; P = 0.032); and (3) a better unassisted patency of AVF (85.9 versus 67.6%; P < 0.01). In conclusion, FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa and survival of the AVF in HD patients through both its thermal and its nonthermal effects.

Entities:  

Mesh:

Year:  2007        PMID: 17267744     DOI: 10.1681/ASN.2006050534

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

Review 1.  Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?

Authors:  Timmy Lee
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 2.  "Venopathy" at work: recasting neointimal hyperplasia in a new light.

Authors:  Alexander S Yevzlin; Micah R Chan; Yolanda T Becker; Prabir Roy-Chaudhury; Timmy Lee; Bryan N Becker
Journal:  Transl Res       Date:  2010-08-13       Impact factor: 7.012

3.  Far infrared radiation (FIR): its biological effects and medical applications.

Authors:  Fatma Vatansever; Michael R Hamblin
Journal:  Photonics Lasers Med       Date:  2012-11-01

Review 4.  Far-infrared therapy for cardiovascular, autoimmune, and other chronic health problems: A systematic review.

Authors:  Shanshan Shui; Xia Wang; John Y Chiang; Lei Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-25

5.  Effects of far-infrared radiation on heart rate variability and central manifestations in healthy subjects: a resting-fMRI study.

Authors:  Yii-Jeng Lin; Yen-Ying Kung; Wen-Jui Kuo; David M Niddam; Chou-Ming Cheng; Chih-Che Chou; Tzu-Chen Yeh; Jen-Chuen Hsieh; Jen-Hwey Chiu
Journal:  Lasers Med Sci       Date:  2014-09-24       Impact factor: 3.161

6.  Usefulness of paclitaxel-releasing high-pressure balloon associated with cutting balloon angioplasty for treatment of outflow stenoses of failing hemodialysis arteriovenous shunts.

Authors:  Anna Maria Ierardi; Marco Franchin; Federico Fontana; Gabriele Piffaretti; Ejona Duka; Massimo Tonolini; Vittorio Miele; Matteo Tozzi; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2016-09-06       Impact factor: 3.469

Review 7.  Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.

Authors:  Nicola C Tanner; Anthony Da Silva
Journal:  Cochrane Database Syst Rev       Date:  2015-07-16

Review 8.  HOming in on arteriovenous fistula survival.

Authors:  W Durante; C-C Lin
Journal:  Kidney Int       Date:  2008-07       Impact factor: 10.612

9.  Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1.

Authors:  Chih-Ching Lin; Xiao-Ming Liu; Kelly Peyton; Hong Wang; Wu-Chang Yang; Shing-Jong Lin; William Durante
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-17       Impact factor: 8.311

10.  p38/AP-1 pathway in lipopolysaccharide-induced inflammatory responses is negatively modulated by electrical stimulation.

Authors:  Deok Jeong; Jaehwi Lee; Young-Su Yi; Yanyan Yang; Kyoung Won Kim; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2013-04-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.